Abstract: In certain embodiments, this disclosure relates to VIP and VIP agonists, optionally conjugated to nanoparticles, for use in methods of treating inflammatory T cell-mediated diseases or conditions, e.g., treating or preventing GvHD. In certain embodiments, this disclosure relates to methods of pulmonary administration of VIP and VIP agonists, optionally conjugated to nanoparticles. In certain embodiments, this disclosure contemplates nanoparticles disclosed herein.

Abstract: The invention is directed to methods of inducing cell recruitment and tissue regeneration at a target site in a subject. It is also based, in part, on the discovery that a subject's own biologic resources and environmental conditions can be used for in situ tissue regeneration and thereby reduce or eliminate the need for donor cell procurement and ex vivo manipulation of such donor cells. Methods are disclosed for recruitment of a subject's own stem cells to a target region by inducing a sustained positive pressure at a target site, such as the kidney, thereby increasing the number of pluripotent cells capable of differentiating to regenerate the target tissue.

Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

Abstract: A peptide consists of the amino acid sequence KLSPTVVGL (SEQ ID NO: 6) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence KLSPTVVGL (SEQ ID NO: 6), an adjuvant, and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor associated T-cell peptide epitopes, alone or in combination with other tumor associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Insulin-like growth factor-binding protein 3 receptor (IGFBP-3R) agonists and methods of their use to treat diseases involving IGFBP-3 and IGFBP-3R are provided. The agonists may be antibodies or other molecules specific for binding to and activating IGFBP-3R. The agonists are used to treat e.g. cancer, metabolic syndrome and obstructive respiratory disorders. In addition, methods of diagnosing cancer and predicting the chance of recurrence, metastasis and/or survival by measuring the level of IGFBP-3R in tumor tissue are provided.

Abstract: The present invention provides methods and compositions related to multivalent carbohydrate antigen structures comprising cancer or infection associated ganglioside carbohydrate antigens. Said carbohydrate structures may be used to induce immunity against said carbohydrate antigens. In some embodiments, carbohydrate structures may be administered to a subject thereby inducing immunity in the subject, for example, the administration of a vaccine comprising said carbohydrate structure. Also provided are methods to induce an immune response in a subject in need thereof by administering said carbohydrate structure. Further provided are methods of producing an antibody or TCR that bind said carbohydrate antigens.

Abstract: The present invention relates to a composition of subunit dengue vaccine comprising a fusion protein of conjugating or connecting delta C nonstructural protein 1 (NS1?C or truncated NS1?C) to at least one polypeptides of NS3c (or truncated NS3c) and/or consensus envelope protein domain III (cEDIII), thereby enhancing better protection against DENV challenge and alleviating associated pathological effects.

Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.

Abstract: The present invention provides mRNA sequences comprising at least one coding region, encoding for at least one epitope of a protein, or of a fragment, variant or derivative thereof, of a virus of the genus rotavirus. Particularly preferred is the protein respectively the protein cleavage product VP8* of rotavirus. The mRNA sequence may be used as a vaccine or generally as a pharmaceutical composition for prophylaxis or treatment of rotavirus infections.

Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.

Abstract: Compositions and methods for enhancing antigen-specific immunity in a subject are provided. Pharmaceutical compositions including an effective amount of an immuno-stimulatory cardiolipin as an adjuvant in combination with an antigen and methods of use thereof for stimulating protective immunity to the antigen in a subject are provided. Administration of the combination of the antigen and cardiolipin adjuvant is effective to enhance antigen-specific immunity in a subject to a greater degree than administering to the subject the same amount of the antigen alone. The active agents can be administered together or separately. In preferred forms the cardiolipin is cardiolipin species (C18:2)4. In preferred forms the antigen is formulated as a vaccine, such as an influenza vaccine. A preferred amount by weight of each reagent is about 10-40% cardiolipin to about 90-60% antigen(s), inclusive.

Abstract: The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.

Abstract: A spiky metal organic framework is provided in the present disclosure. The spiky metal organic framework is formed by a coordination reaction between at least one metal ion and an organic ligand, and includes a body and a plurality of spike-like structures. The body is a spherical shape, and a particle size of the body is 1 ?m to 3 ?m. The spike-like structures are distributed on a surface of the body, a diameter of each spike-like structure is 15 nm to 35 nm, and a length of each spike-like structure is 250 nm to 400 nm.

Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.

Abstract: Methods of encoding and decoding for video data are described for encoding or decoding coefficients for a transform unit. In particular, the sign bits for the non-zero coefficients are encoded using sign bit hiding. Two or more sets of coefficients are defined for the transform unit and a sign bit may be hidden for each set, subject to satisfaction of a threshold test. The sets may correspond to coefficient groups that are otherwise used in multi-level significance map encoding and decoding.

Abstract: The compositions and methods described herein are topically applied to the skin with negligible or no skin irritation and can direct or prevent transport through the skin. The compositions contain neat ionic liquids, optionally in combination with a drug to be delivered. In a preferred embodiment, the compositions increase transdermal transport of the drug to be delivered. In some embodiments, the compositions disrupt bacterial biofilms. This is particularly beneficial in the treatment of antibiotic resistant skin infections. In other embodiments, the compositions direct delivery within the skin. In still other embodiments, the compositions prevent transfer of substances through the stratum corneum. The disclosed compositions and methods can be tuned and modified such that they can be used to treat or prevent a variety of different diseases and disorders.

Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.

Abstract: The present application provides compounds of Formula (B): or pharmaceutically acceptable salts thereof, wherein D is a residue of a biologically active drug, which underdo hydrolysis under physiological conditions to release the biologically active drug and which are useful in the treatment of disorders that could be beneficially treated with the drug.

Abstract: The invention provides a CLIPTAC comprising: (a) a first portion comprising a ligand for an intracellular target protein; (b) a second portion comprising a ligand for an E3 ubiquitin ligase; and (c) a linker portion covalently coupling the first and second portions; wherein the linker comprises a covalent bond produced by a bioorthogonal click reaction between a compatible pair of reactive moieties. CLIPTAC precursor compositions and CLIPTAC precursors are also provided, together with pharmaceutical compositions comprising the CLIPTAC, CLIPTAC precursor compositions and CLIPTAC precursors, and methods of treatment using the same.

Abstract: A pegylated, circularly permuted construct of the CapD enzyme (a gamma glutamyl transferase enzyme acting as a hydrolase specific to poly-?-D-glutamic acid) is used to treat anthrax and other bacterial infections, including but not limited to infection with strains that are resistant to available antibiotics.

Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.

Abstract: Provided herein are methods and compositions for site-specific conjugation of antibodies in the presence of a transglutaminase.

Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of HER2 positive tumors/cancers.

Abstract: The present disclosure relates generally to antibody-drug conjugates comprising peptide-containing linkers and to methods of using these conjugates as therapeutics and/or diagnostics. Also disclosed herein are peptide-containing scaffolds useful to conjugate with a targeting moiety (e.g., an antibody), a drug, or both to produce the antibody-drug conjugates.

Abstract: A method for site-specific quantitation or characterization of drug conjugations of antibody-drug conjugates using protease-assisted drug deconjugation, linker labelling and mass spectrometry, wherein the conjugation includes an attachment linked to a specific conjugation site of a partially conjugated peptide or protein in a sample. The method comprises cleaving a portion of the attachment to generate the peptide or protein containing a cleaved linker, adding a modified linker to an unconjugated conjugation site of the partially conjugated peptide or protein, and subsequently subjecting the sample to mass analysis to identify the peptide or protein containing the cleaved linker and/or the modified linker.

Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins.

Abstract: Disclosed is a complex of a compound of Formula 1, a stereoisomer thereof, or a tautomer of the compound of Formula 1 or stereoisomer thereof, and a cyclodextrin, in which the complex is an amorphous solid. This disclosure also relates to materials and methods for preparing the complex, to pharmaceutical compositions which contain the complex, and to the use of the complex to treat Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.

Abstract: The present disclosure belongs to the technical field of gene therapy, and specifically relates to a series of lipid compounds as well as lipid vectors, nucleic acid lipid nanoparticle compositions, and pharmaceutical preparations containing the same. The compound having the structure of formula (I) provided by the present disclosure may be used in combination with other lipid compounds to prepare a lipid vector, which exhibits pH responsiveness, has high encapsulation efficiency for nucleic acid drugs, and greatly enhances the in-vivo delivery efficiency of nucleic acid drugs. Moreover, it is possible to select lipid compounds with different structures as lipid vectors to adjust the enrichment of nucleic acid drugs in different organs, thereby having good market application prospect.

Abstract: Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.

Abstract: An isolated or purified antisense oligonucleotide targeted to a nucleic acid molecule encoding vascular endothelial growth factor A (VEGF-A) pre-mRNA, wherein the antisense oligonucleotide has a nucleobase sequence selected from the list comprising SEQ ID NO: 1 to SEQ ID NO: 22 which has a modified backbone structure and sequences with at least 95% sequence identity to SEQ ID NO: 1-22 which have a modified backbone structure, and wherein the antisense oligonucleotide inhibits the expression of human VEGF-A.

Abstract: Implantable materials may be used as spacers for separating tissues to reduce a dose of radioactivity received by one of the tissues. Applications include introducing a hydrogel spacer to a position between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location, Further, there may be a step of administering a dose of radioactivity to at least the first tissue location or the second tissue location and/or a step of visualizing margins of the hydrogel spacer. A hydrogel spacer may comprise a polysaccharide and a radioopaque agent and may be used for fiducial marking.

Abstract: Disclosed herein are pharmacologically acceptable magnetic nanoparticles suitable for administration to a subject.

Abstract: A coupling agent composition is provided and includes a plurality of non-toxic components in an amount equal to or greater than 97 weight percent (wt %). The coupling agent composition includes a carrier of water, at least one water soluble polyol selected from the group consisting of propanediol, pentylene glycol, and butylene glycol, a thickening agent having a naturally derived soluble polymer additive selected from a group consisting of xanthan gum, carrageenan, guar, locust bean, sodium hyaluronate, sodium alginate, acacia, tara gum, tamarind seed, succinoglycan, scleroglucan, and mannan, and a balance of incidental impurities.

Abstract: The invention provides a unit operation formed by a device and its use for continuous virus inactivation of a continuous flow of a process fluid. The unit operation formed by a device comprises a single inlet at one end and an outlet at the opposite end and at least one HFI, characterized in that the HFI further comprises at least one installation.

Abstract: A system for sterilizing viruses includes beam generation circuitry for generating a radiating wave having radiating energy therein at a predetermined frequency therein. A controller controls the radiating wave generation at the predetermined frequency. The predetermined frequency equals a resonance frequency of a particular virus. The predetermined frequency induces a mechanical resonance vibration at the resonance frequency of the particular virus within the particular virus for destroying a capsid of the particular virus. Radiating circuitry projects the radiating wave on a predetermined location to destroy the particular virus at the predetermined location.

Abstract: A method of sterilizing and storing laboratory consumables comprises slidably receiving a carrier holding a plurality of laboratory consumables into each of one or more of a plurality of storage compartments within an interior chamber defined in a housing, exposing the plurality of laboratory consumables to ultraviolet (UV) light from a UV lamp positioned above each respective storage compartment and from a UV lamp positioned below each respective storage compartment, determining from which of the plurality of storage compartments a carrier should be removed based on for which carrier a longest period of time has elapsed since going through a predefined sterilization procedure, and indicating to a user into which of the plurality of storage compartments a carrier should be placed or indicating to a user from which of the plurality of storage compartments a carrier should be removed.

Abstract: Embodiments of the present disclosure disclose a multipurpose ultraviolet (UV) floor curing device. The device includes a mobile carriage, a UV panel, and a control device. The mobile carriage is configured to move on a floor applied with a photocurable coating. The UV panel is coupled to the mobile carriage and removably secures a plurality of radiation units configured to emit UV light of a predetermined intensity capable of curing the photocurable coating. The UV panel is configured to transition between a floor configuration and a non-floor configuration. The control device configured to drive the UV panel for the plurality of radiation units to project the UV light towards the ground substantially underneath the UV panel in the floor configuration and towards elevated surfaces proximate to the ground in the non-floor configuration.

Abstract: A fixture system includes a housing configured to be mounted in an upper region of a room or area. A light source is supported by the housing for providing visible light to illuminate at least a portion of the room or area. An ultraviolet radiation (UVR) system is supported by the housing for emitting UVC radiation in an upper region of the room or area. The UVR system includes at least one UVC emitting source and an optic member configured to direct UVC radiation in a pattern having a vertical width dimension that is above a threshold height from a floor or ground in the room or area.

Abstract: A cleaning-disinfecting system may be utilized for one or both of cleaning and/or disinfecting medical devices. The cleaning-disinfecting system may be a portable battery-powered medical device washer-disinfector. The systems, devices, or methods may be specifically designed for use at home or other contexts and can wash and disinfect single or multiple medical devices simultaneously. The cleaning-disinfecting system may automatically reprocess medical devices placed within the cleaning-disinfecting system. The cleaning-disinfecting system may store medical devices after reprocessing without exposing the medical devices to potential contamination from the environment.

Abstract: A sterilization container for sterilizing medical instruments that includes a body defining an interior volume and a lid connected to the body and configured to seal the interior volume between the lid and the body. The lid includes an exterior filter structure including a first plurality of ridges and a first plurality of troughs formed between the first ridges. The container includes a filter assembly connected to the lid and including an interior filter structure including a second plurality of ridges and a second plurality of troughs formed between the second ridges. The first plurality of ridges of the exterior filter structure are interposed between the second plurality of ridges of the interior filter structure. The exterior and interior filter structures are configured to form longitudinal channels positioned between the lid and filter assembly to define a rectangular tortuous filter path that inhibits ingress and egress from the interior volume.

Abstract: A Far UV-C light apparatus has a Far UV-C lamp located within a housing emitting a Far UV-C light having a wavelength of 222±1 nm for destroying pathogens. A quarter wave generator supplies electric energy to the Far UV-C lamp. A handle connected to the housing allows the Far UV-C device to be hand held and moved to a selected location.

Abstract: A controlled release device and method of use, the device comprising a reservoir wherein the reservoir is divided into one or more chambers; a first active material placed in a first chamber of the one or more chambers and at least one second active material placed in at least one other of the one or more chambers wherein the first active material comprises an active ingredient (AI), wherein the AI is one of an insecticide, a spatial repellent, a herbicide or a larvicide; wherein the at least one second active material comprises one or both of a matrix and an altering material; a permeable membrane covering the first chamber; partitions positioned between adjacent chambers of the one or more chambers for dividing the reservoir into chambers such that full or partial removal of one or more of the partitions results in mixing of the first active material and the at least one second active material to form a mixed active material; a cap positioned over the membrane for sealing the reservoir such that removal of

Abstract: The aroma component volatilization device includes a bag containing a heating element that generates heat when exposed to air. At least one surface of the bag is composed of a thermally conductive sheet and a holding sheet. The thermally conductive sheet includes an aluminum layer containing aluminum on at least one entire surface of the sheet. An aroma component L is applied to the holding sheet. The thermally conductive sheet is disposed on the heating element side.

Abstract: An air purification system includes a conduit extending between an inlet and an outlet, each in fluid communication with an enclosed environment. Ambient air from the enclosed environment enters the conduit via the inlet and treated air exits the conduit and enters the enclosed environment via the outlet. The system further includes a fibrous filter disposed within the conduit and configured to treat the ambient air thereby generating the treated air, and a renewal unit disposed within the conduit and configured to renew the fibrous filter.

Abstract: An air purifier for use in a vehicle having louvered air vents includes a housing having rear and front air flow openings that are aligned with and in air flow communication with each other. A louver clip is attached to the housing adjacent the rear air flow opening. The louver clip is configured to engage a louver on an air vent in the vehicle to hold the housing in place in front of the air vent. The air purifier includes an annular ultraviolet light bulb having a central air flow opening aligned with the front and rear air flow openings in the housing. An annular ultraviolet reflector at least partially encircles the annular ultraviolet light bulb. The air purifier includes a power source for providing electrical power to the ultraviolet light bulb, and a power switch for turning power on or off to the ultraviolet light bulb.

Abstract: A respiratory droplet suction device includes an air inlet end and an exhaust end. A plurality of filtering devices are arranged between the air inlet end and the exhaust end. The filtering device is provided with a bacteria filtering screen for adsorbing bacteria and an ultraviolet sterilization lamp for inactivating the bacteria. The filtering device includes a first side wall and a second side wall. The first side wall is connected to the air inlet end, and the second side wall is connected to the exhaust end. The air entering from the first side wall is filtered by the bacteria filtering screen and discharged through the second side wall. The ultraviolet sterilization lamp is arranged corresponding to the bacteria filtering screen. A respiratory droplet filtering apparatus includes the respiratory droplet suction device, and a respiratory droplet electric suction system includes the respiratory droplet filtering apparatus are further provided.

Abstract: An air purifier according to an aspect of the present disclosure includes: an air passage defined between a first inner wall surface and a second inner wall surface that are planar and face each other, having a flat passage cross section in which a distance between the first inner wall surface and the second inner wall surface is small, and meandering in a plane parallel to the first inner wall surface and the second inner wall surface; a catalyst member including a support having a flat mesh shape, and a photocatalyst supported on the support, the catalyst member being disposed parallel to the first inner wall surface and the second inner wall surface in the air passage; and a plurality of light sources dispersed on the second inner wall surface, and configured to irradiate the catalyst member with light that activates the photocatalyst.

Abstract: The present invention relates to a polyvinyl alcohol/sodium alginate/hydroxyapatite composite fibrous membrane, and a preparation method and an application thereof. The preparation method of the composite fibrous membrane includes the following steps: firstly, reacting a diammonium hydrogen phosphate with a calcium nitrate to prepare a hydroxyapatite, and performing ultrasonic dispersion on the hydroxyapatite with a sodium alginate to form a stable hydroxyapatite suspension; separately preparing a sodium alginate solution of which the mass fraction is 2% and a polyvinyl alcohol solution of which the mass fraction is 18% using the above stable hydroxyapatite suspension; and finally, proportionally and uniformly mixing the two solutions, and performing electrospinning.

Abstract: Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.